Literature DB >> 26916616

Prediction of postoperative liver failure using gadoxetic acid-enhanced magnetic resonance imaging in patients with hepatocellular carcinoma.

Young-Joo Jin1, Seung Ho Lee1, Soon Gu Cho2, Jun Ho Kim2, Jin-Woo Lee1, Kun Young Lee3, Woo Young Shin3.   

Abstract

BACKGROUND: We intended to determine the usefulness of gadoxetic acid-enhanced magnetic resonance (MR) imaging on preoperative prediction of the risk of postoperative liver failure (PLF) using measurement of relative liver enhancement (RLE) in patients who underwent surgical resection of hepatocellular carcinoma (HCC).
METHODS: A total of 121 HCC patients who had underwent gadoxetic acid-enhanced MRI before surgery between January 2012 and April 2015 at our hospital was retrospectively analyzed. RLE was calculated as the ratio of signal intensity measurements of the liver parenchyma in each liver segment before and 20 min after intravenous administration of gadoxetic acid. PLF was defined based on the "50-50 criteria" (prothrombin time <50% and serum bilirubin >5 mg/dL on 5 days after surgery).
RESULTS: Of the 121 patients, 74 (61.2%) patients had liver cirrhosis, clinically. Median tumor size 2.8 cm (range, 1-14 cm), 106 (87.6%) patients had a single HCC, and 101 (83.5%) patients had HCC within Milan criteria. Based on the "50-50 criteria", PLF was observed in 7 (5.8%) patients. Mean RLE was significantly lower in patients with PLF than those without it (55.9% vs 85.5%, P < 0.01). In a multivariate analysis, decreased RLE was a significant independent risk factor for PLF in HCC patients (odds ratio 0.97, P = 0.03). Optimal cut-off RLE value was 82.36.
CONCLUSIONS: RLE was significantly lower in patients with PLF than those without it. Measurement of RLE using gadoxetic acid-enhanced MR imaging before surgery can be useful for prediction of PLF in HCC patients who receive surgical treatment.
© 2016 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  gadoxetic acid-enhanced magnetic resonance imaging; hepatocellular carcinoma; postoperative liver failure; relative liver enhancement

Mesh:

Substances:

Year:  2016        PMID: 26916616     DOI: 10.1111/jgh.13327

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  5 in total

1.  Predicting the risk of postoperative liver failure and overall survival using liver and spleen stiffness measurements in patients with hepatocellular carcinoma.

Authors:  Dongbo Wu; Enqiang Chen; Tao Liang; Menglan Wang; Bin Chen; Bai Lang; Hong Tang
Journal:  Medicine (Baltimore)       Date:  2017-08       Impact factor: 1.889

2.  Association between relative liver enhancement on gadoxetic acid enhanced magnetic resonance images and histologic grade of hepatocellular carcinoma.

Authors:  Young-Joo Jin; Soon Gu Cho; Kun Young Lee; Joon Mee Kim; Jin Woo Lee
Journal:  Medicine (Baltimore)       Date:  2017-07       Impact factor: 1.889

3.  Correlation of liver enhancement in gadoxetic acid-enhanced MRI with liver functions: a multicenter-multivendor analysis of hepatocellular carcinoma patients from SORAMIC trial.

Authors:  Osman Öcal; Bora Peynircioglu; Christian Loewe; Otto van Delden; Vincent Vandecaveye; Bernhard Gebauer; Christoph J Zech; Christian Sengel; Irene Bargellini; Roberto Iezzi; Alberto Benito; Kerstin Schütte; Antonio Gasbarrini; Ricarda Seidensticker; Moritz Wildgruber; Maciej Pech; Peter Malfertheiner; Jens Ricke; Max Seidensticker
Journal:  Eur Radiol       Date:  2021-08-31       Impact factor: 5.315

4.  The impact of elastography with virtual touch quantification of future remnant liver before major hepatectomy.

Authors:  Shingo Shimada; Toshiya Kamiyama; Tatsuhiko Kakisaka; Tatsuya Orimo; Akihisa Nagatsu; Yoh Asahi; Yuzuru Sakamoto; Hirofumi Kamachi; Yusuke Kudo; Mutsumi Nishida; Akinobu Taketomi
Journal:  Quant Imaging Med Surg       Date:  2021-06

5.  Post-hepatectomy liver failure after major hepatic surgery: not only size matters.

Authors:  Ulrika Asenbaum; Klaus Kaczirek; Ahmed Ba-Ssalamah; Helmut Ringl; Christoph Schwarz; Fredrik Waneck; Fabian Fitschek; Christian Loewe; Richard Nolz
Journal:  Eur Radiol       Date:  2018-05-16       Impact factor: 5.315

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.